EZS-8

EZS-8, also known as 3-quinazoline-2,4-dione, is a very-low-potency serotonin 5-HT_2A receptor partial agonist related to ketanserin. It has about 0.15% of the potency and 46% of the efficacy of serotonin as a serotonin 5-HT_2A receptor agonist in vitro. The N-benzyl analogue of EZS-8, RH-34, has 250-fold greater potency as a serotonin 5-HT_2A receptor agonist in comparison. EZS-8 was first described in the scientific literature by 1999. N-Benzyl derivatives of EZS-8 like RH-34 had been described as early as 1996 or 1998.